Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

IFRX

InflaRx N.V

Nov 17 • 04:00PM ET

1.24

-0.11 -8.15 %

Healthcare • Biotechnology • Germany • NASD

Peers: AVIR BCRX ALT ARWR CYTK GSK MRNA PFE NVAX SRPT

Index	-	P/E	-	EPS (ttm)	-1.05	Insider Own	6.44%	Shs Outstand	67.75M	Perf Week	-21.52%
Market Cap	83.25M	Forward P/E	-	EPS next Y	-0.77	Insider Trans	0.00%	Shs Float	62.81M	Perf Month	5.08%
Enterprise Value	31.93M	PEG	-	EPS next Q	-0.21	Inst Own	27.65%	Short Float	2.16%	Perf Quarter	40.57%
Income	-61.69M	P/S	462.47	EPS this Y	12.81%	Inst Trans	4.34%	Short Ratio	0.48	Perf Half Y	-29.94%
Sales	0.18M	P/B	1.58	EPS next Y	2.08%	ROA	-54.58%	Short Interest	1.36M	Perf YTD	-49.80%
Book/sh	0.79	P/C	1.59	EPS next 5Y	0.22%	ROE	-62.38%	52W High	2.82 -55.95%	Perf Year	-27.49%
Cash/sh	0.78	P/FCF	-	EPS past 3/5Y	13.25% 18.08%	ROIC	-113.97%	52W Low	0.71 74.33%	Perf 3Y	-51.75%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-457.26%	Volatility	19.73% 14.80%	Perf 5Y	-68.77%
Dividend TTM	-	EV/Sales	177.36	EPS Y/Y TTM	-40.60%	Oper. Margin	-33206.41%	ATR (14)	0.21	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.06	Sales Y/Y TTM	178.84%	Profit Margin	-33446.72%	RSI (14)	45.92	Recom	1.14
Dividend Gr. 3/5Y	- -	Current Ratio	3.33	EPS Q/Q	16.44%	SMA20	-9.65%	Beta	1.47	Target Price	11.63
Payout	-	Debt/Eq	0.02	Sales Q/Q	306.87%	SMA50	-8.72%	Rel Volume	0.59	Prev Close	1.35
Employees	74	LT Debt/Eq	0.02	Earnings	Aug 07 BMO	SMA200	-2.02%	Avg Volume	2.82M	Price	1.24
IPO	Nov 08, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	0.65% -0.65%	Trades		Volume	1,666,040	Change	-8.15%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-02-25	Resumed	H.C. Wainwright	Buy	$6
May-29-25	Downgrade	Raymond James	Strong Buy → Outperform	$2
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight	$10
Apr-05-23	Upgrade	Guggenheim	Neutral → Buy	$8
Feb-28-22	Downgrade	Guggenheim	Buy → Neutral
Oct-28-21	Upgrade	Raymond James	Outperform → Strong Buy	$10 → $14
Mar-11-21	Upgrade	Guggenheim	Neutral → Buy	$16
Nov-06-20	Upgrade	SVB Leerink	Mkt Perform → Outperform	$7 → $10
Oct-08-20	Initiated	H.C. Wainwright	Buy	$11
Jun-17-20	Initiated	BTIG Research	Buy	$12
Apr-30-20	Upgrade	Raymond James	Mkt Perform → Outperform
Jun-05-19	Downgrade	SunTrust	Buy → Hold	$55 → $5
Jun-05-19	Downgrade	Robert W. Baird	Outperform → Neutral	$58 → $6
Jun-05-19	Downgrade	JP Morgan	Overweight → Underweight	$67 → $9
Jun-05-19	Downgrade	Guggenheim	Buy → Neutral	$65 → $6
Jun-05-19	Downgrade	BMO Capital Markets	Outperform → Market Perform	$5
Jan-29-19	Initiated	Robert W. Baird	Outperform
Dec-10-18	Initiated	Credit Suisse	Outperform
Jul-13-18	Initiated	BMO Capital Markets	Outperform	$45
Jun-28-18	Initiated	SunTrust	Buy	$55

Show Previous Ratings

Nov-10-25 07:30AM	InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU) (GlobeNewswire) +28.46%
Nov-07-25 04:05PM	InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria (GlobeNewswire)
Nov-05-25 05:35PM	Jazz Pharmaceuticals (JAZZ) Q3 Earnings and Revenues Beat Estimates (Zacks)
Nov-04-25 08:15AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -7.97%
Oct-21-25 07:20AM	InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference (GlobeNewswire)
08:30AM	Loading…
Sep-12-25 08:30AM	InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) -14.29%
Aug-21-25 07:30AM	InflaRx Announces Participation in September Investor Conferences (GlobeNewswire)
Aug-07-25 08:45AM	InflaRx N.V. (IFRX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:30AM	InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Aug-04-25 08:10AM	Axsome Therapeutics (AXSM) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Jul-31-25 07:30AM	InflaRx to Report Second Quarter 2025 Results on August 7, 2025 (GlobeNewswire)
Jul-25-25 12:22PM	InflaRx Discontinues Pyoderma Gangrenosum Trial, Shifts Focus to INF904 with Summer 2025 Data Expected (Insider Monkey) +5.72%
Jul-11-25 04:15PM	InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement (GlobeNewswire)
Jun-02-25 03:49AM	COVIDs remaining biotech contenders navigate a dwindling market (Pharma Voice)
May-28-25 01:30AM	InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum (GlobeNewswire) -59.86%
07:30AM	Loading…
May-22-25 07:30AM	InflaRx to Participate in Upcoming Investor Conferences (GlobeNewswire) +7.69%
May-07-25 07:30AM	InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) -7.45%
May-06-25 09:35AM	Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
Apr-30-25 07:30AM	InflaRx to Report First Quarter 2025 Results on May 7, 2025 (GlobeNewswire) +17.24%
Apr-02-25 03:33PM	Is InflaRx (IFRX) the Best German Stock to Buy According to Hedge Funds? (Insider Monkey) +9.52%
Mar-26-25 09:35AM	InflaRx (IFRX) Loses -15.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) -6.77%
Mar-20-25 07:30AM	InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones (GlobeNewswire)
Mar-19-25 06:00PM	Here's the major earnings before the open tomorrow (SeekingAlpha) +5.79%
Mar-07-25 08:00AM	InflaRx Showcases Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting (GlobeNewswire)
Feb-28-25 09:00AM	InflaRx to Showcase Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting (GlobeNewswire)
Feb-25-25 07:30AM	InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences (GlobeNewswire)
Feb-18-25 04:01PM	InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants (GlobeNewswire) -5.75%
Feb-13-25 09:45PM	InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants (GlobeNewswire) +5.06% -25.93%
04:01PM	InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants (GlobeNewswire)
Jan-23-25 07:30AM	InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference (GlobeNewswire) -5.20%
11:05AM	Loading…
Jan-16-25 11:05AM	InflaRx wins EU approval for Gohibic in Covid-19-induced ARDS (Pharmaceutical Technology)
Jan-15-25 12:30PM	InflaRx Receives European Commission Approval for GOHIBIC (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS) (GlobeNewswire) +7.69%
Jan-07-25 07:30AM	InflaRx Announces Participation in January Events in San Francisco (GlobeNewswire) +11.35%
Dec-20-24 07:30AM	InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904 (GlobeNewswire) +5.16%
Nov-19-24 06:29PM	Is InflaRx N.V. (IFRX) the Best German Stock to Buy Now? (Insider Monkey) +10.34% +6.25%
Nov-15-24 07:51AM	InflaRx Receives Positive CHMP Opinion for GOHIBIC (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (GlobeNewswire)
Nov-12-24 11:00PM	InflaRx Reports Q3 2024 Financial Results and Progress (TipRanks) +13.25%
Nov-09-24 07:41AM	InflaRx expects cash to fund operations into 2026 (TipRanks)
Nov-08-24 08:40AM	InflaRx N.V. (IFRX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:30AM	InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Oct-31-24 07:30AM	InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference (GlobeNewswire)
Sep-25-24 07:30AM	InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress (GlobeNewswire)
Sep-03-24 07:30AM	InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases (GlobeNewswire)
Aug-27-24 07:30AM	InflaRx Announces Participation in September Investor Events (GlobeNewswire)
Aug-08-24 08:50AM	InflaRx N.V. (IFRX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:30AM	InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Aug-01-24 07:30AM	InflaRx to Report Second Quarter 2024 Results on August 8, 2024 (GlobeNewswire)
Jul-30-24 07:30AM	InflaRx to Present New Preclinical Data on INF904 at the 19th European Meeting on Complement in Human Diseases (GlobeNewswire)
Jun-24-24 08:02AM	InflaRx's GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS) (GlobeNewswire) +8.44%
Jun-05-24 12:00PM	InflaRx Hosts R&D Event Highlighting the Promise of INF904 (GlobeNewswire)
May-21-24 02:30PM	InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators (GlobeNewswire)
May-08-24 11:57AM	IFRX Stock Earnings: InflaRx Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
07:30AM	InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-30-24 07:30AM	InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024 (GlobeNewswire)
Apr-24-24 07:30AM	InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event (GlobeNewswire)
Mar-21-24 11:53AM	IFRX Stock Earnings: InflaRx Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) -8.88%
08:45AM	InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:00AM	InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans (GlobeNewswire)
Mar-19-24 07:30AM	InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024 (GlobeNewswire) +12.67%
Feb-22-24 07:30AM	InflaRx Appoints Jan Medina as Head of Investor Relations (GlobeNewswire)
Jan-25-24 07:30AM	InflaRx Announces Initiation of its Commitment Program for GOHIBIC (vilobelimab) to Help Broaden Access for Eligible Patients (GlobeNewswire) -6.25%
Jan-04-24 07:00AM	InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904 (GlobeNewswire) +14.37%
Dec-01-23 09:55AM	Here's Why InflaRx N.V. (IFRX) Looks Ripe for Bottom Fishing (Zacks)
Nov-28-23 09:35AM	After Plunging -17.65% in 4 Weeks, Here's Why the Trend Might Reverse for InflaRx N.V. (IFRX) (Zacks)
Nov-06-23 09:35AM	InflaRx N.V. (IFRX) Loses -47.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
07:30AM	InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum (GlobeNewswire)
Nov-01-23 07:30AM	InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Oct-31-23 07:12PM	12 Best German Stocks To Buy Now (Insider Monkey)
Sep-11-23 07:00AM	InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904 (GlobeNewswire)
Sep-01-23 02:38PM	InflaRx (IFRX) Skyrockets 110% in Six Months: Here's Why (Zacks) +5.06%
Aug-31-23 10:15AM	Biotech Stock Roundup: FGEN Down on Study Failure, BMY Drug's Label Expansion & More (Zacks)
Aug-30-23 07:30AM	InflaRxs Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA) (GlobeNewswire) +9.89%
Aug-10-23 07:30AM	InflaRx Reports Second Quarter 2023 Financial Results & Operating Update (GlobeNewswire) +9.59%
Jun-28-23 07:30AM	InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer (GlobeNewswire)
Jun-21-23 07:00AM	InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 Patients (GlobeNewswire)
May-11-23 07:30AM	InflaRx Reports First Quarter 2023 Financial and Operating Results and Provides Business Update (GlobeNewswire) +7.46%
May-03-23 07:14AM	InflaRx N.V.'s (NASDAQ:IFRX) Profit Outlook (Simply Wall St.)
Apr-18-23 04:01PM	InflaRx Announces Closing of the Full Exercise of Greenshoe Option Increasing the Proceeds of the Recently Announced Public Offering of Ordinary Shares to US$46 million (GlobeNewswire) +8.73%
Apr-14-23 04:01PM	InflaRx Announces Closing of $40 Million Public Offering of Ordinary Shares (GlobeNewswire)
Apr-13-23 11:22AM	Biotech Stock Roundup: MRNA Provides Update, KALA, IFRX Surge on Regulatory News (Zacks) +6.34%
Apr-11-23 09:08PM	InflaRx Announces Pricing of $40 Million Public Offering of Ordinary Shares (GlobeNewswire) -17.67%
04:00PM	InflaRx Announces Public Offering of Ordinary Shares (GlobeNewswire)
Apr-07-23 10:21AM	Why InflaRx Stock Skyrocketed This Week (Motley Fool)
Apr-05-23 11:57AM	Why Shares of InflaRx Are Soaring Wednesday (Motley Fool) +61.80%
10:49AM	InflaRx (IFRX) Stock Up on FDA's EUA for COVID-19 Treatment (Zacks)
Apr-04-23 04:14PM	UPDATE 1-InflaRx COVID injection gets US FDA's emergency-use authorization (Reuters) +83.90%
02:55PM	InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients (GlobeNewswire)
Mar-23-23 08:21AM	We're A Little Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Rate (Simply Wall St.) -5.43%
Mar-22-23 07:30AM	InflaRx Reports Full Year 2022 Financial and Operating Results (GlobeNewswire) +10.67%
Jan-05-23 07:30AM	InflaRx Provides Update on Planned Phase III Study Design in Pyoderma Gangrenosum with Vilobelimab and Status of its EUA Application in Critically Ill COVID-19 Patients (GlobeNewswire) -5.81%
Dec-21-22 07:30AM	InflaRx Announces Amendment of Co-Development Agreement and Additional Equity Investment by Staidson in Connection with Regulatory Filing in China for Anti-C5a-Antibody for Treatment of COVID-19 (GlobeNewswire) +27.96%
Nov-09-22 07:40AM	InflaRx Initiates First-in-Human Study with Small Molecule C5aR Inhibitor INF904 (GlobeNewswire)
07:30AM	InflaRx Reports Third Quarter 2022 Financial & Operating Results (GlobeNewswire)
Sep-29-22 07:30AM	InflaRx Submits Request for Emergency Use Authorization to US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients (GlobeNewswire)
Sep-09-22 07:30AM	InflaRx to Present at Upcoming Scientific and Investor Conferences (GlobeNewswire) +5.97%
Sep-08-22 07:30AM	InflaRx Announces Vilobelimab Phase III Results in Critically Ill COVID-19 Patients Published in The Lancet Respiratory Medicine (GlobeNewswire) +15.02%
Sep-07-22 10:54AM	Here's Why InflaRx (NASDAQ:IFRX) Must Use Its Cash Wisely (Simply Wall St.)
Aug-17-22 12:00PM	Here's Why InflaRx N.V. (IFRX) is a Great Momentum Stock to Buy (Zacks)
Aug-11-22 12:00PM	InflaRx N.V. (IFRX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Aug-05-22 07:00AM	InflaRx Reports Second Quarter 2022 Financial & Operating Results (GlobeNewswire) -5.21%

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. The company was founded by Niels Christoph Riedemann, Renfeng Guo, and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IFRX

InflaRx N.V

Upgrade your FINVIZ experience